Mesoblast Limited Sponsored ADR MESO 深 滬
已收盤 04-02 16:00:00 美东时间
14.81
-0.990
-6.27%
華盛通- 最 高15.27
- 今 開15.00
- 成交量 17.32万股
- 最 低 14.74
- 昨 收 15.80
- 總市值 19.08亿
- 52周最高 21.50
- 市盈率 靜 --
- 換手率 0.13%
- 52周最低 9.88
- 委 比 98.40%
- 總股本 1.29亿
- 歷史最高 58.4372
- 量 比 0.75
- 振 幅 3.35%
- 歷史最低 1.9406
- 每 手 1
- 風險率 2.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mesoblast shares are trading lower after the company reported worse-than-expected Q4 sales results.
Mesoblast shares are trading lower after the company reported worse-than-expect...
02-28 00:45
Mesoblast H1 EPS $(0.03) Beats $(0.20) Estimate, Sales $51.342M Miss $72.000M Estimate
Mesoblast (NASDAQ:MESO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.20) by 84.5 percent. This is a 99.26 percent increase over losses of $(4.20) per share from the same
02-27 15:44
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
What's Next: Mesoblast's Earnings Preview
Mesoblast (NASDAQ:MESO) is gearing up to announce its quarterly earnings on Thu...
02-26 00:02
Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy
Mesoblast shares fall after new Ryoncil data show high survival in severe GVHD. Company plans adult trial as analysts keep Hold rating and stock trades near key levels.
02-12 21:11
FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain
Mesoblast says FDA feedback supports filing plans for its cell therapy to treat chronic back pain, showing reduced pain and lower opioid use in a late-stage trial.
01-21 02:33
Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales
Mesoblast reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil.
01-10 01:34
Mesoblast shares are trading higher after the company reported a year-over-year increase in December Ryoncil sales results.
Mesoblast shares are trading higher after the company reported a year-over-year...
01-09 22:13
Mesoblast Lapses 3 Million Unquoted Warrants, Slightly Simplifying Capital Structure
The latest announcement is out from Mesoblast ( ($MESO) ). On January 6, 2026, ...
01-07 19:29
Mesoblast Director’s Warrant Lapse Trims Derivative Exposure Without Dilution
Mesoblast Limited ( ($AU:MSB) ) has issued an announcement. Mesoblast has discl...
01-06 15:47
